LeMaitre Vascular, Inc. (NASDAQ:LMAT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On June 7, 2017, Peter R. Gebauer, who serves as President, International, of LeMaitre Vascular, Inc. (the “Company”) and Managing Director of LeMaitre Vascular GmbH, a wholly owned subsidiary of the Company (“GMBH”), submitted his resignation from the Company and all subsidiaries for which he serves as a director or officer, effective September 30, 2017. It is expected that Mr. Gebauer will continue in such positions until such date. In connection therewith, the Company and GMBH entered into certain agreements with Mr. Gebauer, which are described under Item 5.02(e) below.

(e) On June 7, 2017, GMBH entered into a Separation Agreement with Mr. Gebauer (the “Separation Agreement”) to which he has resigned from GMBH, the Company and all subsidiaries for which he serves as a director or officer, effective September 30, 2017. Under the terms of the Separation Agreement, Mr. Gebauer is expected to continue to serve as President, International, of the Company and Managing Director of GMBH as well as in various director and officer roles with other Company subsidiaries until September 30, 2017.

On June 7, 2017, the Company entered into a Transition and Employment Agreement with Mr. Gebauer (the “Transition Agreement”) to which the Company has agreed to reimburse Mr. Gebauer for his expenses in relocating to the United States in an amount up to $74,800, to make a tax equalization payment to Mr. Gebauer for certain 2017 compensation and to employ Mr. Gebauer on a part-time basis until August 15, 2018 as International Operations Specialist for a salary of $10,000 per year. The Company’s obligations under the Transition Agreement are subject to the fulfillment of certain conditions by Mr. Gebauer, including his continued employment by the Company and GMBH through September 30, 2017.

The foregoing description of the Separation Agreement and the Transition Agreement is not complete and is qualified in its entirety by reference to the full texts of such documents, which will be filed with the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2017.

The disclosure regarding compensation of George W. LeMaitre set forth in Item 8.01 below is incorporated by reference into this Item 5.02 to the extent required.

Item 5.07. Submission of Matters to a Vote of Security Holders.

(a) On June 5, 2017, the Company held its 2017 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 18,702,388 shares of the Company’s common stock were entitled to vote as of April 7, 2017, the record date for the Annual Meeting, of which 17,206,665 shares were present in person or represented by proxy at the Annual Meeting.

(b) Matters voted upon by the stockholders at the Annual Meeting were: (i) the election of two Class II directors nominated by the Board of Directors for three-year terms and (ii) the ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for 2017.

Set forth below is information concerning each matter submitted to a vote at the Annual Meeting.

Proposal No. 1 – Election of Directors

By a majority of votes cast, the stockholders elected the following two nominees as Class II directors for a term of three years expiring upon the 2020 Annual Meeting of Stockholders or until his successor has been duly elected and qualified. John A. Roush received a vote of 14,548,849 shares for, 613,786 shares withheld and 2,044,030 broker non-votes. Michael H. Thomas received a vote of 13,426,417 shares for, 1,736,218 shares withheld and 2,044,030 broker non-votes.

Proposal No. 2 – Ratification of the Selection of Independent Registered Public Accounting Firm

By a majority of votes cast, the stockholders ratified the selection of Grant Thornton LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2017 with a vote of 17,180,370 shares for and 17,500 shares against, with 8,795 shares abstaining.

Item 8.01. Other Events.

The Compensation Committee of the Company accepted the offer of George W. LeMaitre, Chairman and Chief Executive Officer, to forego his salary for the remainder of 2017 (except as to the amount legally required under relevant Department of Labor regulations (currently $455 per week)), and to relinquish his bonus opportunity for 2017.

About LeMaitre Vascular, Inc. (NASDAQ:LMAT)

LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.